BACKGROUND:Psoriasis vulgaris is one of the most common chronic skin disorders without any curative treatment. The aim of this study was to investigate the efficacy and safety of HESA-A in the treatment of psoriasis. METHODS: In a randomized, double-blind clinical trial, 28 patients (11 male, 17 female) with chronic plaque-type psoriasis were randomly assigned to treatment and placebo groups. Patients in treatment group received HESA-A tablet 25 mg/kg twice a day orally and control group received placebo with the same method for 6 months and were followed clinically during the study. RESULTS: At the end of study, in the treatment group psoriatic plaques were absent (no evidence of psoriasis or complete remission) in 9 cases (64.2%) and was very mild (controlled, but not entirely cleared) in 5 cases (35.8%). Disease relief was observed in 10 (71.4%) patients after 4 months, in 2 cases (14.3%) after 5 months and in 2 (14.3%) other patients after 6 months while none of the controls showed disease improvement. CONCLUSION: This study showed rapid and good efficacy and safety of HESA-A in the treatment of plaque-type psoriasis.
RCT Entities:
BACKGROUND:Psoriasis vulgaris is one of the most common chronic skin disorders without any curative treatment. The aim of this study was to investigate the efficacy and safety of HESA-A in the treatment of psoriasis. METHODS: In a randomized, double-blind clinical trial, 28 patients (11 male, 17 female) with chronic plaque-type psoriasis were randomly assigned to treatment and placebo groups. Patients in treatment group received HESA-A tablet 25 mg/kg twice a day orally and control group received placebo with the same method for 6 months and were followed clinically during the study. RESULTS: At the end of study, in the treatment group psoriatic plaques were absent (no evidence of psoriasis or complete remission) in 9 cases (64.2%) and was very mild (controlled, but not entirely cleared) in 5 cases (35.8%). Disease relief was observed in 10 (71.4%) patients after 4 months, in 2 cases (14.3%) after 5 months and in 2 (14.3%) other patients after 6 months while none of the controls showed disease improvement. CONCLUSION: This study showed rapid and good efficacy and safety of HESA-A in the treatment of plaque-type psoriasis.
Authors: Brian H May; Anthony L Zhang; Wenyu Zhou; Chuan-Jian Lu; Shiqiang Deng; Charlie C L Xue Journal: Chin J Integr Med Date: 2012-04-02 Impact factor: 1.978